EVALUATING THE EFFICACY OF NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR HER2+ BREAST CANCER
Main Article Content
Keywords
HER2+ breast cancer, Nab-paclitaxel, Neoadjuvant therapy, Triple-negative breast cancer (TNBC), Pathologic response
Abstract
This systematic review and meta-analysis evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a neoadjuvant therapy for HER2+ breast cancer. The analysis compared nab-paclitaxel with conventional paclitaxel treatment, specifically in the context of pathologic response rates and clinical outcomes in different subtypes of HER2+ breast cancer, with a focus on aggressive subtypes like triple-negative breast cancer (TNBC). Our findings suggest that nab-paclitaxel significantly enhances pathologic response rates (ypT0/N0) and improves clinical outcomes compared to paclitaxel, particularly in TNBC cases. Despite its promising results, nab-paclitaxel's safety profile, including increased sensory neuropathy at higher doses, warrants careful consideration. The study also highlights the need for further randomized controlled trials to confirm its superiority over conventional therapies and to explore its potential synergistic effects with other treatments. The role of biomarkers, such as SPARC, in enhancing nab-paclitaxel's specificity for targeting HER2+ breast cancer cells requires further investigation. This meta-analysis supports nab-paclitaxel as a potential alternative to standard neoadjuvant treatments for high-risk or metastatic HER2+ breast cancer, offering new avenues for improved therapeutic strategies.
References
2. Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy. J Natl Cancer Inst Monogr. 2015, 90- 96.
3. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 384, 2014, 164-172.
4. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30, 2012, 1796-1804.
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379, 2012, 432-444.
6. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, et al., Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 21, 2003, 4165-4174.
7. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 379, 2012, 633-640.
8. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, et al. Lapatinib as a component of neoadjuvant therapy for HER2- positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 14, 2013, 1183-1192.
9. Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomized phase 3 trial. Lancet Oncol. 15, 2014, 201-212.
10. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2- positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15, 2014, 747-756.
11. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33, 2015, 13-21.
12. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 34, 2016, 542-549.
13. Tije AJ, Verweij J, Loos WJ, Sparreboom A. et al., Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet. 42, 2003, 665-685.
14. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12, 2006, 1317-1324.
15. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. et al., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23, 2005, 7794-7803.
16. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. et al., Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 27, 2009, 3611-3619.
17. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nabpaclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 20, 2009, 449-453
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr.Sreechandan Reddy
Assistant Professor, Bharath Medical College and Hospital, Selaiyur, Chennai, Tamil Nadu 600073, India.
Dr.Somnath Gupta
Assistant Professor, PSP Medical College Hospital and Research Institute, Oragadam, Sriperumbudur Taluk, Kancheepuram District, Tamil Nadu - 631604